Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff LexingtonCDIX +0.79%27 12-1 Month Momentum % is -75.00% as of Aug. 11, 2026. GuruFocus rates CDIX with a GF Score™ of 27/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 656 Healthcare Providers & Services companies, Cardiff Lexington ranks worse than 98.32% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-11), Cardiff Lexington's 12-1 Month Momentum % is -75.00%.
The industry rank for Cardiff Lexington's 12-1 Month Momentum % or its related term are showing as below:
CDIX's 12-1 Month Momentum % is ranked worse than 98.32% of 656
companies
in the Healthcare Providers & Services industry
Industry Median: -12.725
vs CDIX: -75.00
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Cardiff Lexington 12-1 Month Momentum % Related Terms
CDIX vs AMS, SYRA, BMGL: 12-1 Month Momentum % Comparison
For the Medical Care Facilities subindustry, Cardiff Lexington's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Lexington 12-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cardiff Lexington's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Cardiff Lexington's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -75.00% mean?
Cardiff Lexington (CDIX) has a 12-1 Month Momentum % of -75.00% as of Aug. 11, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Cardiff Lexington and its competitors. According to the industry distribution chart, Cardiff Lexington ranks #645 out of 656 companies in the Healthcare Providers & Services industry, placing it in the top 98.3%.
Is Cardiff Lexington's 12-1 Month Momentum % too high?
Cardiff Lexington's current 12-1 Month Momentum % is -75.00%. Based on the distribution chart, Cardiff Lexington ranks #645 out of 656 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cardiff Lexington has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Lexington's 12-1 Month Momentum % compare to AMS and SYRA?
According to the Healthcare Providers & Services industry distribution chart, Cardiff Lexington ranks #645 out of 656 companies for 12-1 Month Momentum %. This places Cardiff Lexington in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Healthcare Providers & Services company?
A good 12-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Cardiff Lexington and its competitors. Cardiff Lexington's current 12-1 Month Momentum % is -75.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Lexington stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Lexington (CDIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.51 — trading 537.5% above its estimated fair value. The current 12-1 Month Momentum % is -75.00%. Cardiff Lexington's overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Cardiff Lexington (CDIX), the current 12-1 Month Momentum % is -75.00% as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Lexington (CDIX) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Lexington stock appears to be overvalued.
The current stock price of $0.51 is trading 537.5% above its estimated GF Value™ of $0.08.
GuruFocus considers Cardiff Lexington to be Significantly Overvalued.
Key valuation signals for CDIX:
12-1 Month Momentum %: -75.00%
GF Value™: $0.08 vs. price of $0.51 (537.5% above fair value)
No single metric tells the full story. See the CDIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Lexington Corp is an acquisition holding company, conducting its operations through its operating subsidiaries. The company has two reportable operating segments; Healthcare (Nova), and Real Estate (Edge View). The Healthcare segment generates all of the company's revenue and provides a full range of diagnostic and surgical services for injuries and disorders of the skeletal system and associated bones, joints, tendons, muscles, ligaments, and nerves. The Real estate segment consists of Edge View, a real estate company that owns various acres zoned medium-density residential.
27GF Score
Get the complete analysis for CDIX
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIX has been successfully added to your 
